drugset / Trial / NCT04026945

Sustained Release Lidocaine for Treatment of Scrotal Pain

NCT04026945

Phase 1/2 Completed 12 enrolled University of British Columbia
NaSingle-groupOpen-labelTreatment

Summary

In this study, the investigators are testing a new formulation of lidocaine for its suitability in managing chronic scrotal pain (CSCP). The new formulation ST-CP is a lidocaine sustained-release formulation and is expected to provide pain relief over 4 weeks. Currently, the drug lidocaine is not available as an injectable slow-release formulation and chronic scrotal pain patients are often left untreated.

Timeline

Start
2019-10-31
Primary completion
2021-03-24
Completion
2021-03-24

Drugs

EvaluationDrugModalityDoseRoute
Subject Lidocaine Other / unclassified 280 mg Other
Subject Lidocaine Other / unclassified 420 mg Other
Subject Lidocaine Other / unclassified 560 mg Other

Indications